In addition, a remarkable heterogeneity in disease outcomes and metastatic patterns is typically observed among patients, highlighting the need for a deeper understanding of the ROS1+ NSCLC tumor biology (13, 14). The gene discussed is ROS1; the disease is neoplasm.